» Articles » PMID: 37791751

Bacteriophage Steering of Toward Reduced Virulence and Increased Antibiotic Sensitivity

Overview
Journal J Bacteriol
Specialty Microbiology
Date 2023 Oct 4
PMID 37791751
Authors
Affiliations
Soon will be listed here.
Abstract

Antibiotic resistance in bacteria is a growing global concern and has spurred increasing efforts to find alternative therapeutics, such as the use of bacterial viruses, or bacteriophages. One promising approach is to use phages that not only kill pathogenic bacteria but also select phage-resistant survivors that are newly sensitized to traditional antibiotics, in a process called "phage steering." Members of the bacterial genus , which includes various human pathogens, are highly resistant to most antimicrobial agents, including serum immune components, antimicrobial peptides, and polymixin-class antibiotics. However, the application of phages in combination with certain antibiotics can produce synergistic effects that more effectively kill pathogenic bacteria. Herein, we demonstrate that serum resistance is due to intact lipopolysaccharide (LPS) and membranes, and phage-induced resistance altering LPS structure can enhance bacterial sensitivity not only to immune components in serum but also to membrane-associated antibiotics such as colistin. IMPORTANCE Bacteria frequently encounter selection pressure from both antibiotics and lytic phages, but little is known about the interactions between antibiotics and phages. This study provides new insights into the evolutionary trade-offs between phage resistance and antibiotic sensitivity. The creation of phage resistance through changes in membrane structure or lipopolysaccharide composition can simultaneously be a major cause of antibiotic sensitivity. Our results provide evidence of synergistic therapeutic efficacy in phage-antibiotic interactions and have implications for the future clinical use of phage steering in phage therapy applications.

Citing Articles

A flagella-dependent jumbo phage controls rice seedling rot and steers toward reduced virulence in rice seedlings.

Supina B, McCutcheon J, Peskett S, Stothard P, Dennis J mBio. 2025; 16(3):e0281424.

PMID: 39868782 PMC: 11898562. DOI: 10.1128/mbio.02814-24.


Navigating collateral sensitivity: insights into the mechanisms and applications of antibiotic resistance trade-offs.

Mahmud H, Wakeman C Front Microbiol. 2024; 15:1478789.

PMID: 39512935 PMC: 11540712. DOI: 10.3389/fmicb.2024.1478789.


Phage therapy to treat cystic fibrosis complex lung infections: perspectives and challenges.

Canning J, Laucirica D, Ling K, Nicol M, Stick S, Kicic A Front Microbiol. 2024; 15:1476041.

PMID: 39493847 PMC: 11527634. DOI: 10.3389/fmicb.2024.1476041.


New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.

Scoffone V, Barbieri G, Irudal S, Trespidi G, Buroni S Antibiotics (Basel). 2024; 13(1).

PMID: 38247630 PMC: 10812592. DOI: 10.3390/antibiotics13010071.

References
1.
Ahmed M, Zhong L, Shen C, Yang Y, Doi Y, Tian G . Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect. 2020; 9(1):868-885. PMC: 7241451. DOI: 10.1080/22221751.2020.1754133. View

2.
McCutcheon J, Dennis J . The Potential of Phage Therapy against the Emerging Opportunistic Pathogen . Viruses. 2021; 13(6). PMC: 8228603. DOI: 10.3390/v13061057. View

3.
Lauman P, Dennis J . Synergistic Interactions among Complex-Targeting Phages Reveal a Novel Therapeutic Role for Lysogenization-Capable Phages. Microbiol Spectr. 2023; 11(3):e0443022. PMC: 10269493. DOI: 10.1128/spectrum.04430-22. View

4.
Rosales-Reyes R, Saldias M, Aubert D, El-Halfawy O, Valvano M . The suhB gene of Burkholderia cenocepacia is required for protein secretion, biofilm formation, motility and polymyxin B resistance. Microbiology (Reading). 2012; 158(Pt 9):2315-2324. DOI: 10.1099/mic.0.060988-0. View

5.
Lauman P, Dennis J . Advances in Phage Therapy: Targeting the Complex. Viruses. 2021; 13(7). PMC: 8310193. DOI: 10.3390/v13071331. View